Simultaneous Delivery of siRNA and Paclitaxel via a “Two-in-One” Micelleplex Promotes Synergistic Tumor Suppression
- 4 January 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 5 (2), 1483-1494
- https://doi.org/10.1021/nn103349h
Abstract
Combination of two or more therapeutic strategies with different mechanisms can cooperatively prohibit cancer development. Combination of chemotherapy and small interfering RNA (siRNA)-based therapy represents an example of this approach. Hypothesizing that the chemotherapeutic drug and the siRNA should be simultaneously delivered to the same tumoral cell to exert their synergistic effect, the development of delivery systems that can efficiently encapsulate two drugs and successfully deliver payloads to targeted sites via systemic administration has proven to be challenging. Here, we demonstrate an innovative "two-in-one" micelleplex approach based on micellar nanoparticles of a biodegradable triblock copolymer poly(ethylene glycol)-b-poly(ε-caprolactone)-b-poly(2-aminoethyl ethylene phosphate) to systemically deliver the siRNA and chemotherapeutic drug. We show clear evidence that the micelleplex is capable of delivering siRNA and paclitaxel simultaneously to the same tumoral cells both in vitro and in vivo. We further demonstrate that systemic administration of the micelleplex carrying polo-like kinase 1 (Plk1) specific siRNA and paclitaxel can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model, requiring a thousand-fold less paclitaxel than needed for paclitaxel monotherapy delivered by the micelleplex and without activation of the innate immune response or generation of carrier-associated toxicity.This publication has 37 references indexed in Scilit:
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Lipid-like materials for low-dose, in vivo gene silencingProceedings of the National Academy of Sciences of the United States of America, 2010
- Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicinesAdvanced Drug Delivery Reviews, 2009
- Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesProceedings of the National Academy of Sciences of the United States of America, 2007
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences of the United States of America, 2007
- Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomasProceedings of the National Academy of Sciences of the United States of America, 2007
- Designer combination therapy for cancerNature Biotechnology, 2006
- Identification and immunotherapeutic targeting of antigens induced by chemotherapyNature Biotechnology, 2006
- Temporal targeting of tumour cells and neovasculature with a nanoscale delivery systemNature, 2005
- Combined effects of angiostatin and ionizing radiation in antitumour therapyNature, 1998